HUL Acquires Remaining 49% in Zywie for ₹824 Crore, Divests Nutritionalab Stake
HUL is acquiring the remaining 49% stake in Zywie Ventures for ₹824 Crores, making it a wholly owned subsidiary. Additionally, HUL will sell its 19.8% stake in Nutritionalab for ₹307 Crores. Both transactions are expected to close by March 31, 2026. This move aims to strengthen HUL's position in the Health & Wellbeing sector.
The acquisition of a wholly owned subsidiary and the divestment of a minority stake are significant strategic moves that will impact HUL's portfolio and focus in the Health & Wellbeing sector. The financial considerations are substantial.
The acquisition of full ownership in Zywie and the strategic divestment of Nutritionalab are viewed positively as they align with HUL's strategy to focus on core growth areas and leverage its strengths in the Health & Wellbeing segment.
Hindustan Unilever Limited (HUL) announced two strategic decisions concerning its Health & Wellbeing business on February 12, 2026.
The Board of Directors approved the acquisition of the remaining 49% stake in Zywie Ventures Private Limited (Zywie) for a cash consideration of ₹824 Crores. Zywie, along with its subsidiary Zenherb Labs Private Limited, will now become wholly owned subsidiaries of HUL. Zywie reported a turnover of ₹257.67 Crores for the financial year 2024-2025, and its indirect subsidiary Zenherb Labs had a turnover of ₹37.26 Lacs for the same period. This acquisition is expected to be completed by March 31, 2026, subject to fulfillment of customary conditions.
Concurrently, HUL will divest its entire 19.8% shareholding in Nutritionalab Private Limited to USV Private Limited for a consideration of ₹307 Crores. Nutritionalab reported a revenue of ₹118.48 crores for the financial year 2024-25. The sale is also expected to close by March 31, 2026, subject to closing conditions.
Priya Nair, CEO and Managing Director, stated that the full ownership of OZiva (Zywie) aims to unlock the next phase of growth in the Health & Wellbeing sector, leveraging HUL's strengths in science, distribution, and market development.
What to do with a filing like this
Hindustan Unilever Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hindustan Unilever Limited. Read the original for the full detail.